Vijay Pande, a general partner at Andreessen Horowitz and founder of the firm’s a16z Bio+ Health strategy, has announced his departure from the role.

Pande was instrumental in establishing the division, which has raised four funds totaling nearly US$3 billion since it began in 2014, including a US$1.5 billion fund closed in 2022.

The a16z Bio+ Health team will continue to be led by partners Jorge Conde, Julie Yoo, and Vineeta Agarwala.

The team focuses on investing in digital health startups and companies at the intersection of AI, computation, and biology.

Before joining Andreessen Horowitz, Pande was a professor at Stanford University, where he specialized in chemistry, structural biology, and computer science

🔗 Source: TechCrunch

🧠 Food for thought

1️⃣ Biotech venture capital adapting to funding headwinds

The reported downsizing of a16z’s Bio Fund V target to $750 million reflects broader market pressures affecting biotech investing.

This 50% reduction from their previous $1.5 billion fund comes as global venture capital fundraising reached a six-year low in 2024, with just $104.7 billion raised across 865 funds 1.

Digital health funding specifically declined from $10.8 billion in 2023 to $10.1 billion in 2024, demonstrating the challenging fundraising environment 2.

The firm’s strategy appears to be evolving toward more focused capital deployment and strategic partnerships, exemplified by their Biotech Ecosystem Fund with Eli Lilly (up to $500 million commitment), which allows them to maintain significant investment capacity despite the smaller core fund 1.

These adjustments show how even the most established venture firms must adapt to market realities, particularly in capital-intensive sectors like biotech where returns can take longer to materialize.

2️⃣ The evolution of biotech venture from academia to industrial scale

Pande’s career trajectory—from Stanford professor to pioneering venture capitalist—illustrates the broader evolution of computational biology from academic pursuit to commercial enterprise.

When he founded a16z’s Bio+ Health strategy in 2014, the fund started with just $200 million, growing to $450 million for Bio Fund II, and eventually $1.5 billion for Bio Fund IV, demonstrating the rapidly expanding opportunity in engineered biology 31.